Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Daiichi Sankyo
Express Scripts
US Army
Covington
Federal Trade Commission
Julphar
Farmers Insurance
Queensland Health
Harvard Business School

Generated: August 21, 2017

DrugPatentWatch Database Preview

Alcon Company Profile

« Back to Dashboard

What is the competitive landscape for ALCON, and when can generic versions of ALCON drugs launch?

ALCON has forty-six approved drugs.

There is one US patent protecting ALCON drugs. There is one tentative approval on ALCON drugs.

There are eighteen patent family members on ALCON drugs in sixteen countries.

Summary for Applicant: Alcon

Patents:1
Tradenames:42
Ingredients:36
NDAs:46
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Alcon
STATROL
neomycin sulfate; polymyxin b sulfate
SOLUTION/DROPS;OPHTHALMIC062339-001Nov 30, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
Alcon Pharms Ltd
KETOROLAC TROMETHAMINE
ketorolac tromethamine
SOLUTION/DROPS;OPHTHALMIC078721-001Nov 5, 2009ATRXNoNo► Subscribe► Subscribe► Subscribe
Alcon
ISMOTIC
isosorbide
SOLUTION;ORAL017063-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Alcon Pharms Ltd
SULFACETAMIDE SODIUM
sulfacetamide sodium
SOLUTION/DROPS;OPHTHALMIC089068-001May 5, 1987DISCNNoNo► Subscribe► Subscribe► Subscribe
Alcon
PILOPINE HS
pilocarpine hydrochloride
GEL;OPHTHALMIC018796-001Oct 1, 1984DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Alcon

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Alcon Pharms Ltd
BETAXON
levobetaxolol hydrochloride
SUSPENSION/DROPS;OPHTHALMIC021114-001Feb 23, 2000► Subscribe► Subscribe
Alcon Pharms Ltd
TRAVATAN
travoprost
SOLUTION/DROPS;OPHTHALMIC021257-001Mar 16, 2001► Subscribe► Subscribe
Alcon
VEXOL
rimexolone
SUSPENSION/DROPS;OPHTHALMIC020474-001Dec 30, 1994► Subscribe► Subscribe
Alcon
PROFENAL
suprofen
SOLUTION/DROPS;OPHTHALMIC019387-001Dec 23, 1988► Subscribe► Subscribe
Alcon
BETOPTIC PILO
betaxolol hydrochloride; pilocarpine hydrochloride
SUSPENSION/DROPS;OPHTHALMIC020619-001Apr 17, 1997► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ALCON drugs

Drugname Dosage Strength Tradename Submissiondate
travoprost
Ophthalmic Solution0.00%
TRAVATAN
11/28/2008
ketotifen fumarate
Ophthalmic Solution0.03%
ZADITOR
12/23/2004

International Patent Family for Alcon Drugs

Country Document Number Estimated Expiration
Spain2339745► Subscribe
TaiwanI290050► Subscribe
Canada2431368► Subscribe
South Africa200303557► Subscribe
South Korea20030063441► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Alcon Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
00540Netherlands► SubscribePRODUCT NAME: TRAVOPROST; REGISTRATION NO/DATE: EU/1/01/199/001-002 20011127
C/GB03/033United Kingdom► SubscribePRODUCT NAME: ROSUVASTATIN OPTIONALLY IN THE FORM OF A NON-TOXIC PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY THE CALCIUM SALT.; REGISTERED: NL 26872 20021106; NL 26873 20021106; NL 26874 20021106; UK PL 17901/0201 20030321; UK PL 17901/0202 20030321; UK PL 17901/0203 20030321
/2015Austria► SubscribePRODUCT NAME: TOBRAMYCIN ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/10/652/001-003 20110720
2012017Lithuania► SubscribePRODUCT NAME: TRAVOPROSTUM; NAT. REGISTRATION NO/DATE: LT 02/7821/3 20020402; FIRST REGISTRATION: EU/1/01/199/001 - EU/1/01/199/002 20011127
678Luxembourg► SubscribePRODUCT NAME: TOBRAMYCINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE QUI EN DERIVE. FIRST REGISTRATION: 20110725
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Moodys
Johnson and Johnson
US Army
McKesson
Medtronic
Cantor Fitzgerald
Farmers Insurance
Cerilliant
Mallinckrodt
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot